UBRELVY is indicated for the acute treatment of migraine, with or without aura, in adults.
{%lSlanguageSelectorLabel%}
{%lSactiveLanguage%}UBRELVY is indicated for the acute treatment of migraine, with or without aura, in adults.
Clinical use:
UBRELVY is not authorized for pediatric use.
Contraindications:
●Concomitant use with strong CYP3A4 inhibitors.
Relevant warnings and precautions:
●Driving and operating machinery
●Hypersensitivity reactions
●May reduce effectiveness of oral contraceptives
●Use in pregnant or breastfeeding women
●Dose selection in geriatric patients
For more information:
Consult the Product Monograph for important information regarding adverse reactions, drug interactions and dosing information not discussed in this piece. The Product Monograph is also available by calling us at 1-888-704-8271.
Clinical use:
UBRELVY is not authorized for pediatric use.
Contraindications:
●Concomitant use with strong CYP3A4 inhibitors.
Relevant warnings and precautions:
●Driving and operating machinery
●Hypersensitivity reactions
●May reduce effectiveness of oral contraceptives
●Use in pregnant or breastfeeding women
●Dose selection in geriatric patients
For more information:
Consult the Product Monograph for important information regarding adverse reactions, drug interactions and dosing information not discussed in this piece. The Product Monograph is also available by calling us at 1-888-704-8271.
Clinical use:
UBRELVY is not authorized for pediatric use.
Contraindications:
●Concomitant use with strong CYP3A4 inhibitors.
Relevant warnings and precautions:
●Driving and operating machinery
●Hypersensitivity reactions
●May reduce effectiveness of oral contraceptives
●Use in pregnant or breastfeeding women
●Dose selection in geriatric patients
For more information:
Consult the Product Monograph for important information regarding adverse reactions, drug interactions and dosing information not discussed in this piece. The Product Monograph is also available by calling us at
1-888-704-8271.
UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2026 AbbVie. All rights reserved.
CA-UBR-260029A / JN26
UBRELVY and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2026 AbbVie. All rights reserved.
CA-UBR-260029A / JN26
Leave the AbbVie.ca site
You are leaving to a site that is not controlled by AbbVie. The "accept" button below will take you out of AbbVie family of websites. Links which take you out of AbbVie worldwide web sites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience. The inclusion of any link does not imply endorsement of the linked site by AbbVie.